PT  - JOURNAL ARTICLE
AU  - Dorward, David A
AU  - Russell, Clark D
AU  - Um, In Hwa
AU  - Elshani, Mustafa
AU  - Armstrong, Stuart D
AU  - Penrice-Randal, Rebekah
AU  - Millar, Tracey
AU  - Lerpiniere, Chris EB
AU  - Tagliavini, Giulia
AU  - Hartley, Catherine S
AU  - Randle, Nadine P
AU  - Gachanja, Naomi N
AU  - Potey, Philippe MD
AU  - Anderson, Alison M
AU  - Campbell, Victoria L
AU  - Duguid, Alasdair J
AU  - Qsous, Wael Al
AU  - BouHaidar, Ralph
AU  - Baillie, J Kenneth
AU  - Dhaliwal, Kevin
AU  - Wallace, William A
AU  - Bellamy, Christopher OC
AU  - Prost, Sandrine
AU  - Smith, Colin
AU  - Hiscox, Julian A
AU  - Harrison, David J
AU  - Lucas, Christopher D
AU  - ,
TI  - Tissue-specific tolerance in fatal Covid-19
AID  - 10.1101/2020.07.02.20145003
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.02.20145003
4099  - http://medrxiv.org/content/early/2020/07/04/2020.07.02.20145003.short
4100  - http://medrxiv.org/content/early/2020/07/04/2020.07.02.20145003.full
AB  - Background Tissue inflammation is associated with organ dysfunction and death in Covid-19. The efficacy of dexamethasone in preventing mortality in critical Covid-19 suggests that inflammation has a causal role in death. Whether this deleterious inflammation is a direct response to the presence of SARS-CoV-2, or an independent immuno-pathologic process, is unknown.Methods Tissue was acquired from detailed post-mortem examinations conducted on 11 well characterised hospitalised patients with fatal Covid-19. SARS-CoV-2 organotropism was mapped at an organ level by multiplex PCR and sequencing, with cellular resolution achieved by in situ viral spike (S) protein detection. Histological evidence of inflammation and organ injury was systematically examined, and the pulmonary immune response characterized with multiplex immunofluorescence.Findings SARS-CoV-2 was detected across a wide variety of organs, most frequently in the respiratory tract but also in numerous extra-pulmonary sites. Minimal histological evidence of inflammation was identified in non-pulmonary organs despite frequent detection of viral RNA and protein. At a cellular level, viral protein was identified without adjacent inflammation in the intestine, liver and kidney. Severe inflammatory change was restricted to the lung and reticulo-endothelial system. Diffuse alveolar damage, pulmonary thrombi and a monocyte/myeloid-predominant vasculitis were the predominant pulmonary findings, though there was not a consistent association between viral presence and either the presence or nature of the inflammatory response within the lung. Immunophenotyping revealed an influx of macrophages, monocytes and T cells into pulmonary parenchyma. Bone marrow examination revealed plasmacytosis, erythroid dysplasia and iron-laden macrophages. Plasma cell excess was also present in lymph node, spleen and lung. These stereotyped reticulo-endothelial responses occurred largely independently of the presence of virus in lymphoid tissues.Conclusions Tissue inflammation and organ dysfunction in fatal Covid-19 do not map to the tissue and cellular distribution of SARS-CoV-2, demonstrating tissue-specific tolerance. We conclude that death in Covid-19 is primarily a consequence of immune-mediated, rather than pathogen-mediated, organ inflammation and injury.Funding The Chief Scientist Office, LifeArc, Medical Research Scotland, UKRI (MRC).Competing Interest StatementThe authors have declared no competing interest.Funding StatementICECAP receives funding and support from The Chief Scientist Office (RARC-19 Funding Call, Inflammation in Covid-19: Exploration of Critical Aspects of Pathogenesis; COV/EDI/20/10 to D.A.D, C.D.L, C.D.R, J.K.B and D.J.H), LifeArc (through the University of Edinburgh STOPCOVID funding award, to K.D, D.A.D, C.D.L) and Medical Research Scotland (CVG-1722-2020 to D.A.D, C.D.L, C.D.R, J.K.B and D.J.H). C.D.L is a Wellcome Trust Clinical Career Development Fellow (206566/Z/17/Z). J.K.B. and C.D.R. are supported by the Medical Research Council (grant MC_PC_19059) as part of the ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC-4C). D.J.H, I.H.U and M.E are supported by iCAIRD (Industrial Centre for Artificial Intelligence Research in Digital Diagnostics). S.P. is supported by Kidney Research UK and G.T by The Melville Trust for the Cure & Care of Cancer. Identification of SARS-CoV-2 and sequencing work was supported by the United States Food and Drug Administration grant number HHSF223201510104C Ebola Virus Disease: correlates of protection, determinants of outcome and clinical management amended to incorporate urgent COVID-19 studies awarded to J.A.H. R.P.-R. is directly supported by the Medical Research Council Discovery Medicine North Doctoral Training Partnership. The group of J.A.H. is supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. J.A.H. is also funded by the Centre of Excellence in Infectious Diseases Research (CEIDR) and the Alder Hey Charity.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the East of Scotland Research Ethics Service (16/ES/0084).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available on request from the corresponding authors